Turkey
Case Report
Attention Deficit Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Treatment with Olanzapine and Methylphenidate: A Case Report
Author(s): Zeynep Vatansever, Hatice Ünver, Duygu Karagöz, Nursu Çakin Memik and Özlem Yildiz GündogduZeynep Vatansever, Hatice Ünver, Duygu Karagöz, Nursu Çakin Memik and Özlem Yildiz Gündogdu
Attention deficit hyperactivity disorder (ADHD) is one of the most common disorders in childhood which deficits of inattention, hyperactivity and impulsive behavior. Disruptive mood dysregulation disorder is characterized by severe recurrent temper outbursts that are inconsistent with developmental level and manifest verbally or behaviorally. The disorder can co-exist with ADHD and conduct disorder. In treatment of ADHD most common used pharmacological agent is methylphenidate. Atypical antipsychotics (e.g. risperidone, aripiprazole, olanzapine) can be added to treatment in some cases because of unsatisfactory clinical response and comorbidities such as conduct disorder, pervasive developmental disorders, disruptive mood dysregulation disorder, mental retardation. Olanzapine is one of the Food and Drug Administration approved atypical antipsychotics which antagonizing the dopamine (D1.. Read More»
Clinical Depression received 89 citations as per Google Scholar report